The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).
 
Brian T. Hess
Consulting or Advisory Role - ADC Therapeutics; Bristol-Myers Squibb/Celgene
 
Melhem M. Solh
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Seagen
Research Funding - Partner therapeutics
 
Mitul Gandhi
Honoraria - GlaxoSmithKline; Janssen Oncology (Inst); Karyopharm Therapeutics; TG Therapeutics
 
Ying Wang
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Johnson & Johnson (I)
 
Yajuan Qin
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics
Research Funding - ADC Therapeutics
Travel, Accommodations, Expenses - ADC Therapeutics
 
Eric Yu
Employment - ADC Therapeutics
Stock and Other Ownership Interests - ADC Therapeutics; Biomarin; Karuna Therapeutics; Merck; Zentalis
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Graham P. Collins
Honoraria - ADC Therapeutics; AstraZeneca; BeiGene; Celleron Therapeutics; Daiichi Sankyo; Gilead Sciences; Incyte; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - ADC Therapeutics; beigene; Celgene; Celleron Therapeutics; Daiichi Sankyo; Incyte; MSD; Pfizer; Roche; Takeda
Speakers' Bureau - Gilead Sciences; Novartis; Roche; Takeda
Research Funding - Amgen (Inst); BMS (Inst); Celgene (Inst); MSD Oncology (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Roche; Takeda